来那度胺二线治疗老年多中心型Castleman病长期缓解二例报道并文献复习  

Lenalidomideas a Second-line Therapy Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory Multicentric Castleman's Disease:a Report of Two Cases and Literature Review

作　　者：汤杨明[1] 石仁州 蓝梅[1] 李学军[1] 温宗华[2] 陆晓晨 TANG Yangming;SHI Renzhou;LAN Mei;LI Xuejun;WEN Zonghua;LU Xiaochen(Department of Hematology,the People's Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,China;Department of Pathology,the People's Hospital of Guangxi Zhuang Autonomous Region,Nanning 530021,China)

机构地区：[1]广西壮族自治区人民医院血液科,广西壮族自治区南宁市530021 [2]广西壮族自治区人民医院病理科,广西壮族自治区南宁市530021

出　　处：《中国全科医学》2022年第3期368-372,共5页Chinese General Practice

基　　金：广西壮族自治区卫生厅自筹经费课题项目(Z2013331)。

摘　　要：一线治疗失败或复发的老年多中心型Castleman病(MCD)患者尚无标准的治疗方案,国外文献报道来那度胺对于复发/难治的MCD有一定疗效,但中文文献报道较少。本文报道2例来那度胺二线治疗老年复发/难治的MCD患者后取得长期缓解,并对相关文献进行复习,提示来那度胺治疗MCD有效,可以作为治疗复发/难治MCD的一种选择。老年MCD患者本身可能一般状况差,存在各种合并症,从而可能从以来那度胺为基础的治疗方案中获益。No standard therapy is recommended for elderly multicentric Castleman's disease(MCD)patients who failed to the first-line treatment or relapsed.Lenalidomide has been reported to be effective for relapsed/refractory MCD in foreign countries,but its effect on this disease has been rarely reported in China.We reported two elderly patients with relapsed/refractory MCD presented with long-term remission after second-line treatment with lenalidomide,and reviewed relevant literature,then suggested that lenalidomide showed encouraging efficacy in patients with MCD,which may be an attractive alternative for relapsed/refractory MCD.Elderly patients with MCD may be more likely to benefit from lenalidomide-based treatment because of the poor general condition and various complications.

关 键 词：多中心型CASTLEMAN病 老年人 来那度胺 复发 难治病 

分 类 号：R733.4[医药卫生—肿瘤]